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LOWER CARDIAC TROPONIN 
T LEVELS IN PATIENTS 
UNDERGOING 
CARDIOPULMONARY 
BYPASS AND RECEIVING 
HIGH-DOSE APROTININ 
THERAPY INDICATE 
REDUCTION OF 
PERIOPERATIVE 
MYOCARDIAL DAMAGE 
Nowadays in many European heart centers the activation of the fibrinolytic system, 
always occurring during cardiopulmonary bypass, is routinely reduced by high-dose 
application of the proteinase inhibitor aprotinin (total of >4 million KIU). In this 
study parameters of myocardial ischemic injury were investigated with the aim of 
identifying further benefts of aprotinin, particularly the protection of the myocar- 
dium during the ischemic period of aortic crossclamping. Forty patients with 
coronary artery disease who underwent aorta-coronary bypass grafting were ran- 
domly and in a double-blind fashion divided into two groups, one that received 
high-dose aprotinin therapy and one that received only saline solution. Markers 
such as troponin T, with high specificity for detection of myocardial ischemia and 
infarction, and markers with more general specificity such as creatine kinase, its 
isoenzyme, and lactate dehydrogenase showed significantly increased values after 
ischemia in both groups. In patients who received high-dose aprotinin therapy 3 
days after cardiopulmonary bypass all parameters measured showed significantly 
lower levels compared with those in the control group. Therefore we can presume 
that the application of high-dose aprotinin provides myocardial protection from 
perioperative ischemic injury. (J THORAC CARDIOVASC SURG 1995;109:1164-72) 
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D espite well-established procedures such as hypo- thermia and cardioplegia, perioperative myo- 
cardial infarction during cardiopulmonary bypass 
(CPB) still occurs more frequently than in 6% of the 
cases. 1-3 This incidence is still problematic and 
difficult to diagnose in less severe cases. It repre- 
sents an unsolved phenomenon i clinical consider- 
ation of prognostic implications. 1 For diagnosis of 
perioperative myocardial infarction changes in 
plasma concentrations of creatine kinase (CK), its 
isoenzyme (CK-MB), and lactate dehydrogenase 
(LDH) are generally measured in connection with 
analysis of the electrocardiogram or myocardial 
scintigraphy. TM With the development of a new 
one-step enzyme immunoassay for cardiac troponin 
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T by Katus and co-workers 5 a much more cardiac- 
specific and sensitive method for detection of peri- 
operative myocardial ischemic injury is now avail- 
able. 6-8 
Cardiac troponin T belongs to the tropomyosin- 
binding proteins of the troponin regulatory complex, 
which is located on the thin myofilaments (actin, 
tropomyosin, and troponin). It differs from skeletal 
troponin T by 6 to 11 amino acid residues 9'10 and 
therefore if detected in serum is a highly specific 
marker for destruction of cardiac myocytes. 
Postoperative bleeding is still a major complica- 
tion in heart operations, 11' 12 the reasons for which 
are multifactoral: the contact of the blood with the 
artificial devices of the CPB circuit causes a drop in 
platelet count and a reduction in platelet functional 
activity.ll, 13-16 In addition, there is an activation of 
the contact pathway of intrinsic oagulation (that is, 
factor XII and the kallikrein-kinin systems), 17-22 a 
reinforced activation of the fibrinolytic and comple- 
ment systems, 19' 23, 24 and degranulation of neutro- 
phils.2S-a7 
In recent years it has been demonstrated repeat- 
edly that high-dose aprotinin therapy in heart oper- 
ations significantly reduces postoperative blood loss 
by direct and indirect inhibition of fibrinolysis 28-37 
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along with a reduced, probably plasmin-mediated, 
degranulative ffect on the adhesion glycoproteins 
(glycoprotein Ib) of the platelet membrane. 3s-45 
In this randomized ouble-blind study findings in 
40 patients undergoing CPB were investigated for 
further benefits of the serine proteinase inhibitor 
aprotinin with regard to myocardial protection from 
ischemic injury during the period of aortic cross- 
clamping. 
Patients and methods 
Forty patients with coronary artery disease who under- 
went elective aorta-coronary b pass grafting were entered 
in this study. Approval for this study was given by the local 
ethical committee and, after being fully informed verbally, 
all participating patients gave written consent. 
Exclusion criteria were reoperations, preoperative low 
left ventricular function (ejection fraction <-30%, left 
ventricular end-diastolic pressure ->20 mm Hg), preoper- 
ative hemoglobin level 12 gm/dl or less, serum creatinine 
level 2 mg/dl or greater, acquired or hereditary thrombo- 
pathia, allergic diathesis, and previous application of 
aprotinin. Acetylsalicylic acid therapy was stopped at least 
7 days before operation. Patients with preoperative autol- 
ogous blood transfusion or intraoperative or postopera- 
tive infusion of fresh frozen plasma were not accepted. 
Patients were randomly and in a double-blind fashion 
assigned to two groups: 20 patients received high-dose 
aprotinin (Trasylol) and 20 patients were administered 
physiologic saline solution (Table I). Aprotinin and the 
placebo were provided by the manufacturer (Bayer AG, 
Leverkusen, Germany) in identical bottles that differed 
only in the random numbers on their labels. 
Anesthesia was standardized for all patients and in- 
volved induction by fentanyl (Fentanyl-Janssen), thiopen- 
tal (Trapanal), midazolam (Dormicum), and vecuronium 
(Norcuron) and maintenance byfentanyl, midazolam, and 
vecuronium. A dose of 3.5 mg/kg body weight heparin 
(Liquemin) was given shortly before the start of CPB. 
Activated clotting time was measured with the use of 
Hemotec kaolin cartridges (Medtronic Cardiopulmonary, 
Anaheim, Calif.) to avoid artificially prolonged activated 
clotting time values in the presence of aprotinin. 46 If 
activated clotting time levels dropped below 480 seconds 
further heparin was administered. The heparin was antag- 
onized with protamine hydrochloride in the ratio of 1:1 
shortly after extracorporeal circulation (ECC) was com- 
pleted. 
Surgical and bypass procedures were standardized. 
Oxygenation was done by a Cobe CML-Excel mem- 
brane oxygenator (Cobe Laboratories, Lakewood, Colo.) 
with a blood flow of 2.4 L/m 2 per minute in hypothermia 
(rectal temperature 28 ° C). Myocardial protection was 
achieved by 30 ml/kg body weight cold (4 ° C) cardioplegic 
solution (HTK Bretschneider, F. K6hler Chemic, Als- 
bach, Germany). 
Postoperative blood loss was measured by thoracic 
drainage volumes in 2-hour periods until removal of chest 
tubes. 
Serial preoperative and postoperative electrocardio- 
Table I. Blood sampling time and aprotinin/heparin 
application schedule before, during, and after ECC 
Sample Aprotinin and heparin 
No. Sampling time dosage 
1 Preoperative 
Skin cut, loading 30,000 KIU aprotinin/kg 
dose BW in 20 min 
2 Thoracotomy, before 7000 KIU/kg BW per hour 
heparin permanent infusion 
Aortic crossclamping 3.5 mg heparin/kg BW 
3 After 5 rain ECC 30,000 KIU/kg BW in 
priming solution 
4 After 15 min ECC 
5 After 30 rain ECC 
6 After 45 min ECC 
Release of aortic 
crossclamps 
7 Shortly after end of 
ECC 
8 Shortly before end of 
operation 
9 1 day after operation 
10 3 days after opera- 
tion 
10 min after protamine 
Big,, Body weight. 
grams were registered on a 12-channel system and as- 
sessed for the occurrence of new Q waves or a greater 
than 50% R reduction in at least two Chest leads. 
Cardiac muscle troponin T levels were measured by a 
one-step enzyme immunoassay 5 (Boehringer Mannheim, 
Mannheim, Germany) with use of two highly specific 
monoclonal antibodies directed against two different 
epitopes of cardiac troponin T molecule. Levels of en- 
zymes CK, CK-MB, and LDH were determined with test 
kits from Boehringer Mannheim. Monitoring of aprotinin 
plasma levels was conducted according to the method of 
Mueller-Esterl and associates 47 with use of an enzyme- 
linked immunosorbent assay. Kallikrein inhibition capac- 
ity was measured by determining plasma inhibition of 
plasma kallikrein with the chromogenic peptide substrate 
S 2302 (Chromogenix, M61ndal, Sweden). 
Statistical analysis was done by the SPSS statistical 
software package (SPSS Inc., Chicago, Ill.). Results are 
expressed as mean values plus or minus the standard 
deviation. Differences between mean values were assessed 
by univariate analysis of variance and Student's t test. P 
values of 0.05 or less were considered significant. 
Results 
Demography. The distribution of demographic 
data showed homogeneous collectives. The two pa- 
tient groups did not differ significantly in age, 
weight, height, body surface area, red cell volume, 
crossclamping time, number of grafts, or duration of 
operation (Table II). 
Infarction rate. In two patients of the entire 
population perioperative myocardial infarction 
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Table II. Demographic data and distribution of 
operative procedures 
Aprotinin Placebo 
Age (yr) 62.4 _+ 7.4 60.6 + 
Weight (kg) 80.2 _+ 9.4 76.8 -+ 
Height (cm) 173.3 _+ 4.8 171.6 -+ 
Body surface (m 2) 1.9 _+ 0.1 1.9 + 
Red cell volume (L) 2.2 _+ 0,3 2.1 + 
Total operative period (rain) 221.1 _+ 56.6 218.7 -+ 
Crossclamping (min) 88.1 _+ 23.3 93.6 -+ 
No. of venous grafts 0 2,95 _+ 0.89 2.95 _+ 
1 Venous graft 1 0 
2 Venous grafts 5 6 
3 Venous grafts 8 9 
4 Venous grafts 6 5 
Arterial grafts 9 7 
7.7 
7.2 
3.8 
0.1 
0.2 
34.9 
23.9 
0.76 
Values given as mean plus or minus the standard eviation. 
could be diagnosed by new Q waves in electrocar- 
diogram. Both patients came from the placebo 
group and were excluded from statistical analysis of 
all parameters eported. Both cases had the highest 
peak values of CK (628 and 1863 U/L), CK-MB (58 
and 94 U/L), LDH (578 and 1788 U/L), and tropo- 
nin T (18.2 and 12.1 ng/ml). 
Aprotinin monitoring (Fig. 1). Serum aprotinin 
concentrations were determined 15 and 45 minutes 
after total ECC. At both sampling times the concen- 
trations were much higher than the required 200 
KIU/ml. Mean values of the samples were 341.8 _+ 
60.9 and 251.7 + 53.5 KIU/ml, respectively. There- 
fore, analogous to these levels, very high levels of 
kallikrein inhibition capacity up to 387.8% _+ 88.4% 
(sampling time 3) were obtained in the aprotinin 
group. This demonstrates clearly that sufficient 
aprotinin for complete inhibition of plasma kal- 
likrein with use of this regimen of application was 
obtained. 
Blood loss and blood transfusion. Blood loss 
(Fig. 2) from the thoracic drainage volumes when 
the tubes were removed was significantly lower in 
the aprotinin group (p = 0.021). The total in the 
placebo group was 1353.6 _+ 746.5 ml and in the 
group treated with aprotinin was only 878.9 _+ 438.0 
ml. By means of high-dose aprotinin therapy a 
reduction in blood loss of 35.1% could be achieved. 
In the aprotinin group 50% of the patientsdid not 
need any donor blood in comparison with only 18% 
in the control group. Therefore the aprotinin group 
received on average 1.25 units of blood and the 
patients in the placebo group 3.18 units. 
Infarction markers 
Troponin T (Fig. 3). Preoperative values of tropo- 
nin T were below the detectable l vel. Myocardial 
perfusion after the total ECC period showed signif- 
icantly elevated release of troponin T in both 
groups. In the aprotinin group only three patients 
had serum concentrations higher than 5 ng/ml, 
whereas even patients in the control group (without 
the two excluded infarction cases) had concentra- 
tions higher than this level. In all postoperative 
determinations the placebo group without aprotinin 
showed significantly (p -< 0.01) higher values on the 
first postoperative day. 
Enzymes. Elevated CK levels were measured 
postoperatively in the placebo group (Fig. 4). Be- 
cause of the high standard deviation and small 
group size no statistically significant differences 
could be detected, but there was a strong trend 
toward lower values in the aprotinin group. On the 
third postoperative day the control group had a 
mean level of 191.7 _+ 446.4 U/L and the aprotinin 
group only 80.3 + 62.6 U/L. Levels of both the 
isoform CK-MB (Fig. 5) and LDH (Fig. 6) showed a 
large increase after ischemia. Mean values on the 
third postoperative day were significantly lower (p -< 
0.01) in the aprotinin group. 
Discussion 
The results of reduced blood loss from thoracic 
drainages indicate the well-known beneficial effect 
of aprotinin in CPB. We therefore recommend the 
routine application of this proteinase inhibitor to 
minimize blood transfusion and the associated risk 
of infection. 
In this study with high-dose aprotinin therapy we 
were able to demonstrate a suspected protective 
effect on the myocardium. Common enzymatic di- 
agnostic indicators of perioperative myocardial in- 
farction are not specific enough in cardiac opera- 
tions to differentiate between destruction of skeletal 
and myocardial tissues. 7'48 With the use of electro- 
cardiograms or myocardial scintigraphy it is also 
difficult to diagnose myocardial necrosis, especially 
in patients with previous myocardial infarction. We 
therefore only diagnose a perioperative myocardial 
infarction from the electrocardiogram in those pa- 
tients in whom new significant signs of a transmural 
myocardial infarction were displayed after opera- 
tion. Minor changes in the T wave that may be a 
result of multiple causes do not have a sufficient 
diagnostic accuracy. They were therefore not taken 
into consideration for the diagnosis of a periopera- 
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Fig. 1. Black columns (mean -+ standard eviation) show significantly increased kallikrein inhibition (KK/, 
left ordinate) in aprotinin group in correlation with concentrations of aprotinin (line; KIU/ml, right 
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Fig. 2. Cumulative blood loss (mean + standard eviation). Patients treated with high-dose aprotinin had 
significant postoperative reduction i  blood loss from thoracic drainage tubes from first 2 hours after arrival 
(A) in intensive care unit until drainage tube removal (DR). 
tive transmural infarction. Thus a limitation of this 
study is the fact that the perioperative lectrocar- 
diogram does not provide a "gold standard" (which 
other studies confirm 1) with the result that minor 
nontransmural myocardial infarctions cannot be ex- 
cluded in both groups. 
With the introduction of a new one-step enzyme 
immunoassay for cardiac troponin T, 5 an extremely 
sensitive method for detection of myocardial cell 
necrosis is now available. 6-s With this specific 
marker we can detect he efficacy of different pro- 
cedures of myocardial protection and surgical tech- 
niques. All the infarction parameters measured in 
this study showed corresponding results. Incidence 
of new Q waves correlated with markedly increased 
levels of enzymes and troponin T. In nearly all 
patients undergoing CPB ischemic tissue damage 
occurred, but in the group treated with high-dose 
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however, lower values w re seen i patients receiving high-dose aprotinin therapy. 
aprotinin a significantly smaller injury was detect- 
able. 
Fifteen years ago, Diaz and associates 49 con- 
ducted histologic investigations in dogs with re- 
gional ischemia nd found both lower CK levels and 
less myocardial destruction in the aprotinin group. 
Up to now only a few publications have appeared 
that deal with this subject in human beings. Hjelms 
and colleagues 5° foxmd no difference in treatment 
with or without aprotinin in their investigations on 
human CPB. However, they only applied very small 
doses of 200,000 KIU initially and then 20,000 
KIU/hour. On the basis of our experience and 
knowledge to date blood loss and presumably myo- 
cardial protection cannot be influenced with use of 
such a small dosage of aprotinin. 28-36 However, 
corresponding to our results, Sunamori and associ- 
ates 51-53 found lower enzyme levels in patients who 
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significantly ower than those in control group on third day after operation. 
received aprotinin. With the administration of apro- 
tinin by intravenous injections preceding aortic 
clamping, by intracardiac perfusion after aortic 
clamping, or with the use of both methods Gabri- 
elescu and colleagues 54detected normalized histo- 
chemical reactions of proteases together with the 
ultrastructural organization of the myocardial fibers 
in experiments with monkeys, mice, and rats. 
The mechanism of the protective ffect on the 
myocardium cannot yet be explained. One possibil- 
ity is that inhibition of local or circulating kinins, or 
both types of kinins, may be involved inasmuch as 
activation and aprotinin-dependent i hibition of 
kinin systems in CPB have been documented. 33 Our 
results show markedly and significantly enhanced 
kallikrein inhibition in the aprotinin group (Fig. 1). 
Higher levels of kallikrein would lead to increased 
release of bradykinin from high-molecular-weight 
kininogen. Elevated bradykinin levels are possibly 
responsible for increased myocardial capillary per- 
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meability and the occurrence of interstitial edema. 
Additionally, the inhibition of membrane serine 
proteinases by aprotinin may intercept membrane 
permeabilization, thus impairing the proteolytic cas- 
cades tri~gere d by anoxia. Bayley and Fawzi ss 
showed that the application of aprotinin protects the 
myocardial fibers from the lytic action of proteases 
on the sarcolemma by preventing the splitting of 
sarcolemma! fixing sites of Ca 2÷ and the extracellu- 
lar Ca 2+ penetration into the cell. In rabbits with 
experimental myocardial ischemia an aprotinin-de- 
pendent limitation of proteolysis in the cytoplas- 
matic arid tnitochondrial-lysosomal fractions was 
found 55 together with a membrane stabilizing ef- 
fect. 56 
Whatever the reason for its efficacy we suggest 
that high-dose aprotinin therapy in patients under- 
going CPB is of therapeutic benefit not only in 
reducing blood loss, but also in protecting the 
myocardium against ischemic injury. 
This papei" is dedicated to Prof. Dr. W. Heller on his 
sixty-fifth birthday. 
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